Fluidigm and AME Bioscience Team Up in Nordic Distribution Deal

Arrangement Brings Integrated Fluidic Circuit Technology to Nordic Scientists Specializing in Real-Time PCR, Genotyping, Cancer Detection and Absolute Quantification SOUTH SAN FRANCISCO, Calif. & TOROED, Norway–Fluidigm Corporation, the inventor of integrated fluidic circuits, has appointed AME Bioscience as its exclusive distributor for the BioMark™ Systems in the Nordic Region (Norway, Sweden, Iceland, Finland, and Denmark). The BioMark System has significant advantages for real-time PCR, genotyping, cancer detection, and absolute quantification. The BioMark System utilizes integrated fluidic circuits that contain a microscopic matrix of channels, valves and chambers on a silicone based chip that can perform over two thousand experiments at a time. “Fluidigm is committed to bringing the accuracy and efficiency benefits of integrated fluidic circuit technology to life science researchers in the Nordic Region,” said Dominique Remy-Renou, European Vice President of Sales, Fluidigm. “This partnership with AME Bioscience brings our technology and products along with AME’s first-rate customer support to the scientists of this region.” “We are thrilled to partner with Fluidigm to bring integrated fluidic circuit technology to our customers,” said Alister Ewing, Director AME Bioscience. “We hope to serve as the catalyst in bringing the benefits of integrated fluidic circuit technology and Fluidigm’s BioMark System to Nordic researchers.” About Fluidigm Fluidigm develops, manufactures and markets proprietary Integrated Fluidic Circuit (IFC) systems that significantly improve productivity in life science research. Fluidigm’s IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These “integrated circuits for biology” are made possible by miniaturizing and integrating liquid handling components on a single microfabricated device. Fluidigm’s IFC systems, consisting of instrumentation, software and single-use IFCs, increase throughput, decrease costs and enhance sensitivity compared to conventional laboratory systems. Fluidigm products have not been cleared or approved by the Food and Drug Administration for use as a diagnostic and are only available for research use. About AME Bioscience AME Bioscience has developed a large customer base in the Nordic Region of automated DNA analysis systems, protein analysis and mass spectrometry systems. The Nordic business focuses mostly on applications of DNA analysis closer to disease identification with innovative and patented PCR technologies as well as new and rapid fluorescent DNA analysis systems. AME Bioscience aims to enhance the technologies it provides to enable scientists to better discover healthcare benefits and to more specifically and rapidly identify and diagnose disease.

< | >